Melevodopa/carbidopa (Sirio) vs Parcopa
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Parkinson's Disease
Shared mechanism: dopamine precursor · full Parkinson's Disease pipeline
Melevodopa/carbidopa (Sirio)
Marketed by Chiesi Farmaceutici
NCT00491998 · Phase 1/2 · completed
The study was randomized and double-blind, with a planned enrollment of 27 participants and a comparison with standard levodopa/carbidopa tablets. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Reported efficacy
to characterise the plasma concentrations of L-dopa after repeated doses of V1512 in fluctuating PD patients compared to standard L-dopa/carbidopa (Sinemet) over the course of the day (4 weeks): L-dopa accumulation from first to final dose across Cohorts 1/2/3: mean AUC0-t increase V1512 51%/50%/85% vs standard L-dopa/carbidopa 92%/93%/150%; mean Cmax increase V1512 30%/14%/52% vs standard 64%/23%/99%. (not_applicable)
Result source: NCT00491998
Parcopa
Rights held by UCB; US product discontinued
NCT00139867 · Phase 3 · completed
The study used randomization and a conventional carbidopa/levodopa comparator, but it was open-label and focused on treatment preference rather than a hard clinical outcome. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Reported efficacy
Onset of action: time to a 30% decrease in UPDRS Motor Exam (Part III) total score after identical doses of Parcopa and Sinemet: Onset times were similar: 43 minutes vs 47 minutes (Sinemet vs Parcopa, respectively)
Result source: NCT00139880
Results for Parkinson's Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Melevodopa/carbidopa (Sirio) | Parcopa |
|---|---|---|
| OFF time, change | —Not reported | —Not posted · NCT00139880 |
| ON time without troublesome dyskinesia, change | —Not reported | —Not posted · NCT00139880 |
| UPDRS Part III, change | —Not reported | —Not posted · NCT00139880 |
| MDS-UPDRS Part II, change | —Not reported | —Not posted · NCT00139880 |
OFF time, change
- Melevodopa/carbidopa (Sirio)
- —Not reported
- Parcopa
- —Not posted · NCT00139880
ON time without troublesome dyskinesia, change
- Melevodopa/carbidopa (Sirio)
- —Not reported
- Parcopa
- —Not posted · NCT00139880
UPDRS Part III, change
- Melevodopa/carbidopa (Sirio)
- —Not reported
- Parcopa
- —Not posted · NCT00139880
MDS-UPDRS Part II, change
- Melevodopa/carbidopa (Sirio)
- —Not reported
- Parcopa
- —Not posted · NCT00139880
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Melevodopa/carbidopa (Sirio): 0 of 4 rows · Parcopa: 2 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Parcopa |
|---|---|
| Dropout rate | —a NCT00590122 · Phase 4 · registry result, not featured evidence |
| Discontinued due to AEs | —a NCT00590122 · Phase 4 · registry result, not featured evidence |
| Serious AEs | 0%a NCT00590122 · Phase 4 · registry result, not featured evidence |
| Most frequent reported AEs |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Parcopa
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Melevodopa/carbidopa (Sirio)'s landscape · Parcopa's landscape